The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Drug repurposing from an academic perspective
Open accessAbstract
Academia and small business research units are poised to play an increasing role in drug discovery, with drug repurposing as one of the major areas of activity. Here we summarize project status for a number of drugs or classes of drugs: raltegravir, cyclobenzaprine, benzbromarone, mometasone furoate, astemizole, R-naproxen, ketorolac, tolfenamic acid, phenothiazines, methylergonovine maleate and beta-adrenergic receptor drugs, respectively. Based on this multi-year, multi-project experience we discuss strengths and weaknesses of academic-based drug repurposing research. Translational, target and disease foci are strategic advantages fostered by close proximity and frequent interactions between basic and clinical scientists, which often result in discovering new modes of action for approved drugs. On the other hand, lack of integration with pharmaceutical sciences and toxicology, lack of appropriate intellectual coverage and issues related to dosing and safety may lead to significant drawbacks. The development of a more streamlined regulatory process world-wide, and the development of pre-competitive knowledge transfer systems such as a global healthcare database focused on regulatory and scientific information for drugs world-wide, are among the ideas proposed to improve the process of academic drug discovery and repurposing, and to overcome the “valley of death” by bridging basic to clinical sciences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Double identity for proteins of the Bcl-2 family
Reed, J. C. (1997) · Nature · doi:10.1038/42867 · Cited by 1,475
Self-citationChong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Quorum Sensing in Staphylococci
Novick, R. P., & Geisinger, E. (2008) · Annual Review of Genetics · doi:10.1146/annurev.genet.42.110807.091640 · Cited by 958
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Translational and Clinical Science — Time for a New Vision
Zerhouni, E. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmsb053723 · Cited by 728
Privileged Structures: Applications in Drug Discovery
DeSimone, R., Currie, K., Mitchell, S., Darrow, J., & Pippin, D. (2004) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207043328544 · Cited by 577
Coyne, C. B., & Bergelson, J. M. (2006) · Cell · doi:10.1016/j.cell.2005.10.035 · Cited by 547
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401
Fluorogen-activating single-chain antibodies for imaging cell surface proteins
Szent-Gyorgyi, C., Schmidt, B. F., Creeger, Y., Fisher, G. W., Zakel, K. L., Adler, S., Fitzpatrick, J. A. J., Woolford, C. A., Yan, Q., Vasilev, K. V., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1368 · Cited by 390
Self-citationNIH Molecular Libraries Initiative
Austin, C. P., Brady, L. S., Insel, T. R., & Collins, F. S. (2004) · Science · doi:10.1126/science.1105511 · Cited by 348
Lee, M.-H. H., Graham, G. G., Williams, K. M., & Day, R. O. (2008) · Drug Safety · doi:10.2165/00002018-200831080-00002 · Cited by 309
A surface on the androgen receptor that allosterically regulates coactivator binding
Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708036104 · Cited by 307
Phenothiazine: the seven lives of pharmacology's first lead structure
Ohlow, M. J., & Moosmann, B. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.001 · Cited by 280
Integrating virtual screening in lead discovery
Oprea, T. I., & Matter, H. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.008 · Cited by 250
Self-citationComparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins
Zhai, D., Jin, C., Satterthwait, A. C., & Reed, J. C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401937 · Cited by 234
Self-citationCripe, L. D., Uno, H., Paietta, E. M., Litzow, M. R., Ketterling, R. P., Bennett, J. M., Rowe, J. M., Lazarus, H. M., Luger, S., & Tallman, M. S. (2010) · Blood · doi:10.1182/blood-2010-04-277269 · Cited by 233
Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
Flow cytometry for high-throughput, high-content screening
Edwards, B. S., Oprea, T., Prossnitz, E. R., & Sklar, L. A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.007 · Cited by 206
Self-citationMore forks on the road to replication stress recovery
Allen, C., Ashley, A. K., Hromas, R., & Nickoloff, J. A. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq049 · Cited by 152
Self-citationLee, S., Oshige, M., Durant, S. T., Rasila, K. K., Williamson, E. A., Ramsey, H. E., Corwin, L. K., Nickoloff, J. A., & Hromas, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503676102 · Cited by 150
Self-citationOverview of the Hatch-Waxman Act and its impact on the drug development process.
Gj, M. (1999) · PubMed · Cited by 133
ASTEMIZOLE-INDUCED TORSADE DE POINTES
Simons, F. E. R., Kesselman, M., Giddins, N. G., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90656-3 · Cited by 126
Oprea, T. I., Nielsen, S. K., Ursu, O., Yang, J. J., Taboureau, O., Mathias, S. L., Kouskoumvekaki, I. A., Sklar, L. A., & Bologa, C. (2011) · Molecular Informatics · doi:10.1002/minf.201100023 · Cited by 115
Self-citationCollins, F. S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3461 · Cited by 109
Kitada, S., Kress, C. L., Krajewska, M., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113647 · Cited by 106
Opportunities for Research and NIH
Collins, F. S. (2009) · Science · doi:10.1126/science.1185055 · Cited by 97
The prince and the pauper. A tale of anticancer targeted agents
Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 94
Ivnitski‐Steele, I. D., Larson, R. A., Lovato, D. M., Khawaja, H. M., Winter, S. S., Oprea, T. I., Sklar, L. A., & Edwards, B. S. (2008) · Assay and Drug Development Technologies · doi:10.1089/adt.2007.107 · Cited by 66
Self-citationInhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus
Schröer, J., & Shenk, T. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810740105 · Cited by 62
Chigaev, A., Waller, A., Amit, O., Halip, L., Bologa, C., & Sklar, L. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901178200 · Cited by 56
Self-citationIdentify drug repurposing candidates by mining the Protein Data Bank
Moriaud, F., Richard, S. B., Adcock, S. A., Chanas, L., Surgand, J.-S., Jelloul, M. B., & Delfaud, F. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr017 · Cited by 54
Mestres, J., Seifert, S. A., & Oprea, T. I. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.177 · Cited by 50
Self-citationHunter, A. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.009 · Cited by 49
Libby, E. N., & Hromas, R. (2010) · Blood · doi:10.1182/blood-2010-09-304311 · Cited by 49
Self-citationThe CTSA Pharmaceutical Assets Portal – a public–private partnership model for drug repositioning
Marusina, K., Welsch, D. J., Rose, L. M., Brock, D., & Bahr, N. J. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.06.006 · Cited by 37
Surviladze, Z., Young, S. M., & Sklar, L. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-442-1_17 · Cited by 33
Self-citationIntegration of virtual and physical screening
Fara, D. C., Oprea, T. I., Prossnitz, E. R., Bologa, C., Edwards, B. S., & Sklar, L. A. (2006) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2006.11.003 · Cited by 32
Self-citationHaynes, M. K., Strouse, J. J., Waller, A., Leitão, A., Curpan, R. F., Bologa, C., Oprea, T. I., Prossnitz, E. R., Edwards, B. S., Sklar, L. A., et al. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109335671 · Cited by 31
Self-citationCould pharma open its drug freezers?
Mullard, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3473 · Cited by 30
Curpan, R. F., Simons, P. C., Zhai, D., Young, S. M., Carter, M. B., Bologa, C., Oprea, T. I., Satterthwait, A. C., Reed, J. C., Edwards, B. S., et al. (2011) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0363 · Cited by 29
Self-citationWinter, S. S., Lovato, D. M., Khawaja, H. M., Edwards, B. S., Steele, I. D., Young, S. M., Oprea, T. I., Sklar, L. A., & Larson, R. S. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108314610 · Cited by 29
Self-citationSerotonin syndrome in a patient taking Lexapro and Flexeril: a case report
Day, L. T., & Jeanmonod, R. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2008.03.028 · Cited by 20
Gillman, P. K. (2009) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2009.03.001 · Cited by 15
Breathing New Life into Old Drugs: Indication Discovery by Systems Directed Therapy
Bundscherer, A., & Hafner, C. M. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_24 · Cited by 7
Cited by
SwissTargetPrediction: a web server for target prediction of bioactive small molecules
Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., & Zoete, V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku293 · Cited by 1,791
Review of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Shifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Drug repurposing from the perspective of pharmaceutical companies
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13798 · Cited by 429
Challenges and opportunities of drug repositioning
Novac, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.004 · Cited by 374
Metadata
- Authors
- Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., Hromas, R., Hudson, L., Mackenzie, D. A., Muller, C. Y., Reed, J. C., Simons, P. C., Smagley, Y., Strouse, J., Surviladze, Z., Thompson, T., Ursu, O., Waller, A., Wandinger-Ness, A., Winter, S. S., Wu, Y., Young, S. M., Larson, R. S., Willman, C., & Sklar, L. A.
- Venue
- Drug Discovery Today: Therapeutic Strategies
- Publisher
- Elsevier BV
- Published
- 2011
- Volume
- 8
- Issue
- 3-4
- Pages
- 61-69
- ISSN
- 1740-6773 (ISSN-L)
- OpenAlex
- W2080754816
- Cited by
- 364
- References
- 46
- FWCI
- 12.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.